Fig. 4
From: Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?
Cost-effectiveness Acceptability Curve A question 1 simulation; B question 2 simulation. SOF Sofosbuvir, VEL Velpatasvir, LDV Ledipasivr
Fig. 4 | Cost Effectiveness and Resource Allocation